| |
| |
|
| Insider
Information: |
Lampert Mark N |
| Relationship: |
10% Owner |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
44 |
|
| Direct
Shares |
110,762,579 |
|
|
Indirect Shares
|
88,557,834 |
|
|
| Direct
Value |
$1,430,535,692 |
|
|
|
Indirect Value
|
$1,617,324,755 |
|
|
| Total
Shares |
199,320,413 |
|
|
| Total
Value |
$3,047,860,447 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
50
|
13
|
|
Stock
price went up :
|
40
|
4
|
| Stock
price went down : |
10
|
9
|
| |
|
|
|
Gain/Loss Ratio : |
4.0
|
4.0
|
| Percentage
Gain/Loss : |
 103.0%
|
 -82.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Arena Pharmaceuticals Inc |
ARNA |
Director, 10% Owner |
2003-10-17 |
0 |
2003-10-17 |
4,520,212 |
Premium* |
|
|
Repligen Corp |
RGEN |
10% Owner |
2009-05-15 |
3,216,850 |
|
0 |
Premium* |
|
|
Dynavax Technologies Corp |
DVAX |
Indirect Beneficial Ow... |
2009-06-19 |
6,193,051 |
2009-06-19 |
18,579,153 |
Premium* |
|
|
Adolor Corp |
ADLR |
10% Owner |
2009-09-22 |
4,123,551 |
2009-09-22 |
12,370,653 |
Premium* |
|
|
Gyre Therapeutics |
GYRE |
10% Owner |
|
0 |
2012-11-08 |
1,052,258 |
Premium* |
|
|
Arqule Inc |
ARQL |
10% Owner |
2018-05-30 |
771,305 |
2010-04-05 |
12,624,219 |
Premium* |
|
|
Astex Pharmaceuticals Inc |
ASTX |
10% Owner |
2010-04-20 |
5,583,399 |
2010-04-20 |
16,750,197 |
Premium* |
|
|
Capstone Therapeutics Corp |
CAPS |
See Explanation of Res... |
2011-06-27 |
0 |
2017-07-14 |
890,487 |
Premium* |
|
|
Ligand Pharmaceuticals Inc |
LGND |
See Explanation of Res... |
|
0 |
2014-03-25 |
130,175 |
Premium* |
|
|
Icagen Inc |
ICGN |
10% Owner |
2011-09-07 |
0 |
2011-09-07 |
625,400 |
Premium* |
|
|
Palatin Technologies Inc |
PTN |
10% Owner |
|
0 |
2014-02-27 |
2,494,521 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2011-10-10 |
0 |
2011-10-12 |
3,527,700 |
Premium* |
|
|
Kent International Inc |
KNTH |
See Explanation of Res... |
2011-12-23 |
0 |
2011-12-23 |
0 |
Premium* |
|
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
|
0 |
2012-11-06 |
3,750,277 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
|
0 |
2013-06-07 |
7,761,738 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
2013-06-05 |
0 |
2015-02-05 |
1,898,293 |
Premium* |
|
|
Tobira Therapeutics Inc |
TBRA |
See Explanation of Res... |
|
0 |
2014-03-21 |
1,121,221 |
Premium* |
|
|
Cti Biopharma Corporation |
CTIC |
See Explanation of Res... |
2023-06-26 |
0 |
2023-06-26 |
0 |
Premium* |
|
|
Infinity Pharmaceuticals Inc |
INFI |
10% Owner |
2021-02-11 |
534,847 |
2016-12-01 |
0 |
Premium* |
|
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2023-01-06 |
1,693,924 |
2023-01-06 |
361,774 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2017-06-20 |
201,811 |
2017-05-09 |
0 |
Premium* |
|
|
Glycomimetics Inc |
GLYC |
10% Owner |
2020-11-04 |
630,453 |
|
0 |
Premium* |
|
|
Xenon Pharmaceuticals Inc. |
XENE |
10% Owner |
2018-03-27 |
59,464 |
2017-06-06 |
0 |
Premium* |
|
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2019-06-10 |
169,589 |
2017-10-19 |
0 |
Premium* |
|
|
Syndax Pharmaceuticals Inc |
SNDX |
10% Owner |
2018-06-18 |
85,038 |
2018-06-18 |
0 |
Premium* |
|
|
Immune Design Corp. |
IMDZ |
10% Owner |
2018-12-04 |
370,391 |
2018-12-04 |
0 |
Premium* |
|
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
2023-05-11 |
20,333,557 |
2019-01-30 |
0 |
Premium* |
|
|
Calithera Biosciences, Inc. |
CALA |
10% Owner |
2020-05-21 |
480,432 |
|
0 |
Premium* |
|
|
Five Prime Therapeutics Inc |
FPRX |
10% Owner |
2021-03-04 |
6,262,085 |
|
0 |
Premium* |
|
|
Cytokinetics Inc |
CYTK |
See Explanation of Res... |
2020-12-09 |
463,244 |
2019-12-10 |
0 |
Premium* |
|
|
Merus Nv |
MRUS |
10% Owner |
2021-10-08 |
232,747 |
|
0 |
Premium* |
|
|
Ideaya Biosciences, Inc. |
IDYA |
See Explanation of Res... |
2021-02-02 |
233,150 |
2020-06-19 |
0 |
Premium* |
|
|
Kymera Therapeutics, Inc. |
KYMR |
See Remarks and Footno... |
2023-11-03 |
294,632 |
2020-08-21 |
0 |
Premium* |
|
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
10% Owner |
2023-05-05 |
145,029 |
|
0 |
Premium* |
|
|
Olema Pharmaceuticals, Inc. |
OLMA |
Director, 10% Owner |
2023-09-12 |
524,151 |
2023-09-14 |
99,556 |
Premium* |
|
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2020-12-18 |
5,468,599 |
|
0 |
Premium* |
|
|
Rain Therapeutics Inc. |
RAIN |
See Remarks; Former 10... |
2024-01-25 |
0 |
2021-04-23 |
0 |
Premium* |
|
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2023-11-16 |
548,938 |
|
0 |
Premium* |
|
|
Verastem, Inc. |
VSTM |
10% Owner |
2022-01-25 |
19,630,934 |
|
0 |
Premium* |
|
|
ESSA Pharma Inc |
EPIX |
10% Owner |
2022-07-11 |
8,561,841 |
|
0 |
Premium* |
|
|
Third Harmonic Bio, Inc. |
THRD |
10% Owner |
2022-12-20 |
241,309 |
2022-12-20 |
0 |
Premium* |
|
|
Structure Therapeutics Inc. |
GPCR |
10% Owner |
2023-05-10 |
5,173,941 |
|
0 |
Premium* |
|
|
Engene Holdings Inc. |
ENGN |
10% Owner |
2023-10-31 |
2,221,445 |
|
0 |
Premium* |
|
|
Allakos Inc. |
ALLK |
10% Owner |
2024-01-16 |
16,312,872 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
355 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 13 of 15
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RAIN |
Rain Therapeutics Inc. |
10% Owner |
– – • |
2021-07-06 |
4 |
B |
$15.25 |
$4,113,276 |
D/D |
269,723 |
149,480 |
2.45 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
10% Owner |
– – • |
2019-06-10 |
4 |
S |
$10.70 |
$4,134,799 |
D/D |
(386,289) |
169,589 |
0 |
- |
|
| CALA |
Calithera Biosciences, In... |
10% Owner |
– – • |
2019-10-29 |
4 |
B |
$2.60 |
$4,157,340 |
D/D |
1,598,977 |
589,558 |
2.45 |
- |
|
| RPTX |
Repare Therapeutics Inc. |
10% Owner |
– – • |
2023-11-15 |
4 |
B |
$5.00 |
$4,657,687 |
D/D |
931,556 |
532,795 |
2.45 |
- |
|
| RAIN |
Rain Therapeutics Inc. |
10% Owner |
– – • |
2021-07-01 |
4 |
B |
$15.65 |
$4,965,416 |
D/D |
317,279 |
132,500 |
2.45 |
- |
|
| XOMA |
XOMA Corporation |
10% Owner |
– – • |
2020-12-11 |
4 |
B |
$25.00 |
$5,000,000 |
I/I |
200,000 |
200,000 |
1.5 |
% |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2018-05-30 |
4 |
S |
$5.00 |
$5,179,799 |
D/D |
(1,035,939) |
771,305 |
0 |
- |
|
| CNCE |
Concert Pharmaceuticals, ... |
10% Owner |
– – • |
2017-10-19 |
4 |
B |
$15.84 |
$5,256,720 |
D/D |
331,916 |
291,788 |
2.45 |
- |
|
| GLYC |
Glycomimetics Inc |
10% Owner |
– – • |
2019-09-05 |
4 |
B |
$3.18 |
$5,309,950 |
D/D |
1,668,746 |
528,891 |
2.45 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
10% Owner |
– – • |
2014-02-19 |
4 |
S |
$73.03 |
$5,477,497 |
I/I |
(75,000) |
84,749 |
0 |
- |
|
| MRUS |
Merus Nv |
10% Owner |
– – • |
2021-03-16 |
4 |
B |
$23.00 |
$5,749,900 |
D/D |
250,000 |
427,377 |
2.45 |
% |
|
| INFI |
Infinity Pharmaceuticals ... |
10% Owner |
– – • |
2018-06-19 |
4 |
B |
$1.65 |
$5,802,324 |
D/D |
3,516,560 |
1,130,366 |
2.45 |
- |
|
| MRUS |
Merus Nv |
10% Owner |
– – • |
2021-03-30 |
4 |
B |
$19.75 |
$5,925,000 |
D/D |
300,000 |
462,015 |
2.45 |
% |
|
| RAIN |
Rain Therapeutics Inc. |
10% Owner |
– – • |
2022-01-07 |
4 |
B |
$12.00 |
$5,956,620 |
D/D |
496,385 |
185,388 |
2.45 |
- |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2010-04-01 |
4 |
S |
$5.81 |
$6,467,977 |
D/D |
(1,113,000) |
4,811,073 |
0 |
- |
|
| RAIN |
Rain Therapeutics Inc. |
10% Owner |
– – • |
2021-09-13 |
4 |
B |
$16.49 |
$6,468,516 |
D/D |
392,269 |
169,992 |
2.45 |
- |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2018-04-04 |
4 |
S |
$2.90 |
$6,674,585 |
D/D |
(2,301,581) |
1,164,374 |
0 |
- |
|
| ARQL |
Arqule Inc |
10% Owner |
– – • |
2018-04-18 |
4 |
S |
$3.10 |
$6,914,156 |
D/D |
(2,230,373) |
947,118 |
0 |
- |
|
| CYTK |
Cytokinetics Inc |
See Explanation of Responses |
– – – |
2020-12-09 |
4 |
S |
$18.00 |
$7,757,172 |
D/D |
(430,954) |
463,244 |
0 |
% |
|
| CTIC |
Cti Biopharma Corporation |
See Explanation of Responses |
– • • |
2022-08-09 |
4 |
S |
$6.12 |
$7,891,336 |
I/I |
(1,289,434) |
6,148 |
0 |
% |
|
| RPTX |
Repare Therapeutics Inc. |
10% Owner |
– – • |
2022-06-03 |
4 |
B |
$12.29 |
$7,912,725 |
D/D |
644,044 |
406,416 |
2.45 |
- |
|
| XOMA |
XOMA Corporation |
10% Owner |
– – • |
2019-12-19 |
4 |
B |
$22.00 |
$8,210,290 |
D/D |
373,195 |
1,103,314 |
2.45 |
- |
|
| RAIN |
Rain Therapeutics Inc. |
See Explanation of Responses |
– • • |
2022-11-08 |
4 |
B |
$5.83 |
$9,971,387 |
D/D |
1,710,358 |
341,547 |
3.92 |
- |
|
| KYMR |
Kymera Therapeutics, Inc. |
See Explanation of Responses |
– – – |
2022-01-24 |
4 |
B |
$37.76 |
$10,300,637 |
D/D |
272,767 |
1,343,743 |
2.44 |
- |
|
| XOMA |
XOMA Corporation |
10% Owner |
– – • |
2019-12-18 |
4 |
OE |
$22.00 |
$10,389,896 |
D/D |
472,268 |
159,537 |
0 |
- |
|
355 Records found
|
|
Page 13 of 15 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
